Showing 1861-1870 of 2314 results for "".
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- Sandoz Closes Deal to Acquire Ranibizumab Biosimilar Cimerli from Coherushttps://modernod.com/news/sandoz-closes-deal-to-acquire-ranibizumab-biosimilar-cimerli-from-coherus/2482144/Sandoz has completed the acquisition of the US biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences. In January, in a move to pay down debt and focus on its oncology business, Coherus BioSciences entered into an agreement to divest its Cimerli (ranibiz
- Optos Celebrates Milestones: 25,000 Devices Installed Globally and Extensive Clinical Publications Achievedhttps://modernod.com/news/optos-celebrates-milestones-25000-devices-installed-globally-and-extensive-clinical-publications-achieved/2482131/Optos announced a dual milestone achievement of over 25,000 devices installed worldwide, and the collection of 2,500 clinical and peer-reviewed studies spanning 235 disease states, acccording to a company news release. "This remarkable double milestone reflects the unwavering
- Alcon to Unveil Updated MARLO App at SECO 2024https://modernod.com/news/alcon-to-unveil-new-marlo-app-at-seco-2024/2482127/Alcon announced it will showcase the new MARLO App at the SECO International meeting in Atlanta. The app includes new features for patients and is now available to download in the Apple App Store. Launched in 2020, MARLO was developed as an online platform to h
- SightGlass Vision Receives FDA Breakthrough Device Designation for Myopia Spectacle Lenshttps://modernod.com/news/sightglass-vision-receives-fda-breakthrough-device-designation/2482118/The FDA has granted Breakthrough Device designation to SightGlass Vision's Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children. The design is the first to use the contrast management mechanism of action, incorporating thousan
- New Penn Study Finds Promising Model for Restoring Cone Functionhttps://modernod.com/news/new-penn-study-finds-promising-model-for-restoring-cone-function/2482111/Vision scientists from the Division of Experimental Retinal Therapies at the University of Pennsylvania School of Veterinary Medicine used functional magnetic resonance imaging (fMRI) to assess brain responses to lights that stimulate only cone cells in dogs with naturally occurrin
- Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japanhttps://modernod.com/news/nicox-and-kowa-enter-into-agreement-for-ncx-470-development-and-commercialization-in-japan/2482106/Nicox SA announced the signature of an agreement granting Kowa exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop for the lowering of IOP in patients with glaucoma or ocular hypertension. Under the
- Coherus Divest Ophthalmology Franchise to Sandoz in $170 Million Dealhttps://modernod.com/news/coherus-divest-ophthalmology-franchise-to-sandoz-in-170-million-deal/2482075/In a move to pay down debt and focus on its oncology business, Coherus BioSciences has entered into an agreement to divest its Cimerli (ranibizumab-eqrn) ophthalmology franchise to Sandoz for $170 million in cash, plus Cimerli inventory costs. This divestiture includes Co
- Nidek and Orbis International Partner to Scale Up Artificial Intelligence Eye Screenings in Vietnamhttps://modernod.com/news/nidek-and-orbis-international-partner-to-scale-up-artificial-intelligence-eye-screenings-in-vietnam/2482060/Nidek announced a donation to Orbis International to support Orbis’s artificial intelligence-based screening services in Vietnam. The donation of six specialized fundus cameras, which take images of the retina, will support the scale up of Orbis’ AI-based diabetic retinopathy scr
- Harrow Launches Dry Eye Drug Vevye in the United Stateshttps://modernod.com/news/harrow-introduces-vevye-in-united-states-for-treatment-of-signs-and-symptoms-of-dry-eye-disease/2482053/Harrow announced that Vevye (cyclosporine ophthalmic solution) 0.1% is now available in the United States. It is indicated for treating the signs and symptoms of dry eye disease (DED). Vevye is the company’s nonpreserved, twice-daily dosed prescription drug based on a water free s